Citations
42
10.5 per year
Published
2021
Durability of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in high-burden HIV countries: a multinational cohort study
The Lancet HIV•2021
Authors
M Nanfuka, LA Mwesigwa, S Nsanzimana, JI Forrest, A Fowler, K Gill, E Remera, A Binagwaho, EJ Mills
The Lancet
HIV/AIDS
Antiretroviral Therapy
Abstract
Background: Non-nucleoside reverse-transcriptase inhibitor (NNRTI)-based regimens are commonly used in HIV treatment programs in sub-Saharan Africa. We assessed the long-term durability of NNRTI-based antiretroviral therapy in high HIV burden countries.
Related Publications
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial
The Lancet Global Health • 2022
The Lancet
COVID-19
Validating a shortened depression scale (10 item CES-D) among HIV-positive people in British Columbia, Canada
PLoS One • 2012
HIV/AIDS
Interventions to improve adherence to antiretroviral therapy: a systematic review and network meta-analysis
The Lancet HIV • 2017
The Lancet
HIV/AIDS